How a Week in Philly May Have Changed the Future for a Medtech CEO

Marvin Barron describes himself as a Philadelphia CEO, but his company isn’t a Philly company. Yet.

Research at Pearl Antigenics is based out of a lab at Washington State University, Barron said, but his team is now thinking about non-university homes. The Queen Village resident is considering a few cities around the country, including his hometown — which is looking more favorable after a recent event.

“I’ve got to say,” Barron told, “coming through the Capital Readiness Program has really moved Philadelphia up the list.”